AGIO Agios Pharmaceuticals Inc.

73.56
-0.41  -1%
Previous Close 73.97
Open 74.23
Price To Book 5.18
Market Cap 4265933891
Shares 57,992,576
Volume 503,686
Short Ratio 14.84
Av. Daily Volume 341,983

SEC filingsSee all SEC filings

  1. 8-K - Current report 181053864
  2. 8-K - Current report 181053818
  3. CT ORDER - Confidential treatment order 181035919
  4. CT ORDER - Confidential treatment order 181030316
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986840

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial to be initiated 4Q 2018.
AG-348
Thalassemia
FDA Approval announced July 20, 2018.
Ivosidenib
IDH1m Relapsed/Refractory AML - cancer
Phase 3 trial initiation announced June 18, 2018.
AG-348
Pyruvate kinase deficiency
Phase 3 initiated 2Q 2017.
AG-120 and VIDAZA - AGILE
Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer
Global Phase 3 study for AG-221 initiated October 2015. Continues to enroll as of January 2018.
Enasidenib (AG-221) - IDHENTIFY
Refractory Acute myeloid leukemia (AML) - cancer
Approval announced August 1, 2017.
IDHIFA (enasidenib) - AG-221
Advanced hematologic malignancies with an IDH2 mutation
Phase 3 initiated December 2016. Enrollment to be completed 1H 2019.
AG-120 Ivosidenib
IDH1 mutant positive cholangiocarcinoma - cancer
Phase 1 data at ASCO June 2018 noted CR rate was 24%.
AG-120 Ivosidenib
R/R Acute Myeloid Leukemia (AML)
Phase 1/2 updated data at ASCO June 2018. ORR of 78%, CR Rate of 44%.
Enasidenib or ivosidenib with VIDAZA
Frontline AML with IDH1 or IDH2 mutation
Phase 1 first data presented at ASH 2017 with updated data due at ASH 2018. Phase 3 trial to be initiated 4Q 2018.
Ivosidenib or enasidenib
Frontline AML with IDH1 or IDH2 mutation
Phase 1 dosing of first patient announced March 19, 2018.
AG-270
Solid tumors
Phase 1 data presented at ASCO June 1, 2018. 1 minor response + 1 partial response out of 93 patients.
AG-881
Glioma

SEC Filings

  1. 8-K - Current report 181053864
  2. 8-K - Current report 181053818
  3. CT ORDER - Confidential treatment order 181035919
  4. CT ORDER - Confidential treatment order 181030316
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18986840
  6. 8-K - Current report 18986649
  7. UPLOAD [Cover] - SEC-generated letter
  8. 8-K - Current report 18961827
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter